

Dr. Pamela Kirby



(1953, British)

Initial appointment: 2016

Proposed term of office: 2020 - 2024

- Non-Executive Director Reckitt Benckiser Plc.
- Non-Executive Director Hikma Pharmaceuticals Plc.
- Non-Executive Director DCC Plc.
- Former Senior Independent Director Victrex Plc., former CEO of Quintiles Transnational Corp, former Regional Director and VP of Corporate Strategic Planning at AB Astra (now Astra Zeneca Plc) and former Director of Global Strategic Marketing and Planning at F. Hoffmann-La Roche Ltd.

Dr. Kirby's current term of office ends this year. She has confirmed that she is available to be reappointed for another term of four years. Dr. Kirby was appointed as a member of the Supervisory Board in 2016. Since September 2016, Dr. Kirby is a member of the Nomination Committee and the Remuneration Committee. Dr. Kirby holds a PhD. in clinical Pharmacology and has an extensive background and strong record in international commercial and strategic management across pharmaceutical, chemical, business service and other publicly listed enterprises.

Dr. Kirby provides a positive contribution to the Supervisory Board of AkzoNobel, which the Supervisory Board would like to see continued. In accordance with the articles of association of Akzo Nobel N.V., the Supervisory Board therefore proposes that Dr. Kirby is appointed for a second term of four years as a member of AkzoNobel's Supervisory Board, with effect from April 24, 2020. If appointed, it is the intention of the Supervisory Board that Dr. Kirby will remain a member of the Nomination Committee and the Remuneration Committee.

On April 23, 2020 Dr. Kirby will comply with all relevant regulations for reappointment as member of the Supervisory Board.

Dr. Kirby holds no ordinary shares in the company.